Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M El-Omar

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Contemporary Clinical Trials|December 6, 2025
Personalising the management of obesity-related asthma using medical nutrition therapy and physical activity prescription: The IDEAL study protocolTamara Blickisdorf, Lisa G Wood, Sarah R Valkenborghs, et al.
The Lancet. Infectious Diseases|September 28, 2019
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chih-Min Chang, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2023
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trialsMei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, et al.
Nature Microbiology|August 22, 2022
Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventionsZhengzheng Yan, Boxuan Chen, Yuqiong Yang, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Gut|June 20, 2022
Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junctionKentaro Sugano, Stuart Jon Spechler, Emad M El-Omar, et al.
Gut|July 11, 2025
<i>Helicobacter pylori</i> antibiotic resistance: a global challenge in search of solutionsChristian Schulz, Jyh-Ming Liou, Mohamed Alboraie, et al.
Gut|October 2, 2020
Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensusJyh-Ming Liou, Peter Malfertheiner, Yi-Chia Lee, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Contemporary Clinical Trials|December 6, 2025
Personalising the management of obesity-related asthma using medical nutrition therapy and physical activity prescription: The IDEAL study protocolTamara Blickisdorf, Lisa G Wood, Sarah R Valkenborghs, et al.
The Lancet. Infectious Diseases|September 28, 2019
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chih-Min Chang, et al.
The Lancet. Gastroenterology & Hepatology|May 13, 2023
Molecular testing-guided therapy versus susceptibility testing-guided therapy in first-line and third-line Helicobacter pylori eradication: two multicentre, open-label, randomised controlled, non-inferiority trialsMei-Jyh Chen, Po-Yueh Chen, Yu-Jen Fang, et al.
Nature Microbiology|August 22, 2022
Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventionsZhengzheng Yan, Boxuan Chen, Yuqiong Yang, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Gut|June 20, 2022
Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junctionKentaro Sugano, Stuart Jon Spechler, Emad M El-Omar, et al.
Gut|July 11, 2025
<i>Helicobacter pylori</i> antibiotic resistance: a global challenge in search of solutionsChristian Schulz, Jyh-Ming Liou, Mohamed Alboraie, et al.
Gut|October 2, 2020
Screening and eradication of <i>Helicobacter pylori</i> for gastric cancer prevention: the Taipei global consensusJyh-Ming Liou, Peter Malfertheiner, Yi-Chia Lee, et al.
Pageof 16